$AAPG News
Last published 44m ago
- 44m agoAAPGAscentage Pharma Announces Inclusion of Lisaftoclax in China's 2026 National Reimbursement Drug List and Successful Renewal of Coverage for OlverembatinibGlobeNewswireROCKVILLE, Md., Nov. 15, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, today announced that its two core assets are covered by China's 2026 National Reimb ...
- 1w agoAAPGAscentage Pharma to Present Data from Multiple Trials, Including an Oral Presentation of APG-5918 at ASH 2026GlobeNewswireROCKVILLE, Md., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ:AAPG, HKEX: 6855)), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery,
- 1w agoAAPGAscentage Pharma to Participate in Two Upcoming Investor Conferences in LondonGlobeNewswireROCKVILLE, Md., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ:AAPG, HKEX: 6855)) ("Ascentage Pharma" or the "Company"), a global, commercial-stage, integrated
- 3w agoAAPGAscentage Pharma’s Lisaftoclax Granted Breakthrough Therapy Designation in China for Treatment-Naïve CLL/SLLGlobeNewswireROCKVILLE, Md., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ:AAPG, HKEX: 6855)), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development
- 2mo agoAAPGAscentage Pharma to Participate in Four Upcoming Investor ConferencesGlobeNewswireROCKVILLE, Md., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ:AAPG, HKEX: 6855)) ("Ascentage Pharma" or the "Company"), a global, commercial-stage, integrated
- 2mo agoAAPGASCENTAGE PHARMA 1H 2026 EARNINGS - ASCENTAGE PHARMA GROUP INTERNATIONALEarnings Call TranscriptsHello, and welcome to the 2026 Interim Financial Results. We ask that you please hold all questions until the completion of the formal remarks, at which time you will be given instructions for the question and answer ses
- 2mo agoAAPGASCENTAGE PHARMA 1H 2026 EARNINGS - ASCENTAGE PHARMA GROUP INTERNATIONALEarnings Call TranscriptsHello, and welcome to the 2026 Interim Financial Results. We ask that you please hold all questions until the completion of the formal remarks, at which time you will be given instructions for the question and answer ses
- 2mo agoAAPGAscentage Pharma Reports 2026 Interim Unaudited Financial Results and Provides Business UpdatesGlobeNewswireRevenue for the first half of 2026 increased 29% year-over-year to US$44.5 million (RMB302.2 million), primarily attributable to increased product sales. Expanded executive leadership with appointments of Dr. Faical
- 3mo agoAAPGAscentage Pharma to Participate in the Evercore 2nd Annual China Biotech SummitGlobeNewswireROCKVILLE, Md., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ:AAPG, HKEX: 6855)) ("Ascentage Pharma" or the "Company"), a global, commercial-stage, integrated
- 3mo agoAAPGCORRECTION: Ascentage Pharma to Report 2026 Six Month Interim Results and Provide Corporate Update on August 19, 2026GlobeNewswireIn a release issued under the same headline earlier today by Ascentage Pharma Group International (NASDAQ:AAPG, HKEX: 6855)),please note that in the first paragraph of the release, the time should be 7:00 am Eastern
- 3mo agoAAPGAscentage Pharma to Report 2026 Six Month Interim Results and Provide Corporate Update on August 19, 2026GlobeNewswireROCKVILLE, Md., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ:AAPG, HKEX: 6855)) ("Ascentage Pharma" or the "Company"), a global, commercial-stage, integrated
- 3mo agoAAPGAscentage Pharma Appoints Dr. Faiçal Miyara as Chief Business Officer and Jim Ziegler as Chief Commercial OfficerGlobeNewswireROCKVILLE, Md., Aug. 02, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ:AAPG, HKEX: 6855)), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development
- 3mo agoAAPGAscentage Pharma Chairman and CEO Dr. Dajun Yang Named to The Medicine Maker Power List 2026GlobeNewswireROCKVILLE, Md. and SUZHOU, China, July 26, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ:AAPG, HKEX: 6855)), a global, commercial-stage, integrated biopharmaceutical company engaged in the
- 5mo agoAAPGAscentage Pharma Presents Multiple Clinical Updates at EHA2026 CongressGlobeNewswirePoster presentations from ongoing clinical trials of two core assets, olverembatinib and lisaftoclax, highlight global innovation capabilities in hematologic malignancies ROCKVILLE, Md. and SUZHOU, China, June 14, 2026
- 5mo agoAAPGAscentage Pharma Presents Updated Clinical Data for Olverembatinib as Second-Line Therapy in CML-CP at ASCO 2026GlobeNewswireROCKVILLE, Md. and SUZHOU, China, May 31, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ:AAPG, HKEX: 6855)), a global, commercial-stage, integrated biopharmaceutical company engaged in the
- 5mo agoAAPGAscentage Pharma Presents Its First Dataset on MDM2-p53 Inhibitor Alrizomadlin (APG-115) in Pediatric Solid Tumors at ASCO 2026GlobeNewswireROCKVILLE, Md. and SUZHOU, China, May 31, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ:AAPG, HKEX: 6855)), a global, commercial-stage, integrated biopharmaceutical company engaged in the
- 5mo agoAAPGAscentage Pharma Presents Data on Olverembatinib in CML-LBP and Ph+ BCP-ALL at ASCO 2026GlobeNewswireROCKVILLE, Md. and SUZHOU, China, May 31, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ:AAPG, HKEX: 6855)), a global, commercial-stage, integrated biopharmaceutical company engaged in the
- 5mo agoAAPGAscentage Pharma Releases Latest Clinical Data from Multiple Trials at ASCO 2026GlobeNewswireROCKVILLE, Md. and SUZHOU, China, May 21, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ:AAPG, HKEX: 6855)), a global, commercial-stage, integrated biopharmaceutical company engaged in the
- 6mo agoAAPGAscentage Pharma to Present 17 Clinical Advances at 2026 European Hematology Association CongressGlobeNewswireROCKVILLE, Md. and SUZHOU, China, May 12, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ:AAPG, HKEX: 6855)), a global, integrated biopharmaceutical company engaged in the discovery, development
- 6mo agoAAPGAscentage Pharma to Participate in Three Upcoming Investor ConferencesGlobeNewswireROCKVILLE, Md. and SUZHOU, China, May 12, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ:AAPG, HKEX: 6855)) ("Ascentage Pharma" or the "Company"), a global, commercial stage, integrated
- 6mo agoAAPGAscentage Pharma to Present Data from Multiple Trials, Including Three Rapid Oral Presentations, at ASCO 2026GlobeNewswireROCKVILLE, Md. and SUZHOU, China, April 21, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ:AAPG, HKEX: 6855)), a global, commercial stage, integrated biopharmaceutical company engaged in the
- 7mo agoAAPGAscentage Pharma to Present Four Promising Preclinical Studies Demonstrating the Potential of Combination Therapies at American Association for Cancer Research (AACR) 2026 Annual MeetingGlobeNewswireROCKVILLE, Md. and SUZHOU, China, April 19, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ:AAPG, HKEX: 6855)), a global, commercial stage, integrated biopharmaceutical company engaged in the
- 7mo agoAAPGAscentage Pharma Reports Full Year 2025 Unaudited Financial Results and Provides Business UpdatesGlobeNewswireProduct sales and commercial rights revenues in 2025 increased 90% year-over-year to US$82.1 million (RMB574.1 million)Sales of Olverembatinib increased 81% year-over-year to US$62.2 million (RMB435.3 million) Sales of
- 8mo agoAAPGAscentage Pharma to Participate in Three Upcoming Investor ConferencesGlobeNewswireROCKVILLE, Md. and SUZHOU, China, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ:AAPG, HKEX: 6855)) ("Ascentage Pharma" or the "Company"), a global, commercial stage, integrated
- 9mo agoAAPGAscentage Pharma to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026GlobeNewswireROCKVILLE, Md. and SUZHOU, China, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ:AAPG, HKEX: 6855)) ("Ascentage Pharma" or the "Company, a global, commercial stage, integrated
- 9mo agoAAPGAscentage Pharma Announces IND Clearance by the China CDE for BTK Degrader APG-3288GlobeNewswireROCKVILLE, Md. and SUZHOU, China, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ:AAPG, HKEX: 6855)), a global, commercial stage, integrated biopharmaceutical company engaged in the
- 10mo agoAAPGAscentage Pharma Outlined its Global Innovation Strategy During Presentation at 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswireTwo commercialized hematology products, Olverembatinib and Lisaftoclax, drive dual-engine growth with strong China market presenceNext-generation BTK protein degrader APG-3288 receives IND clearance from the U.S. FDA,
- 10mo agoAAPGAscentage Pharma Announces IND Clearance by the U.S. Food and Drug Administration for BTK Degrader APG-3288GlobeNewswireNovel next-generation Bruton tyrosine kinase (BTK)-targeted protein degrader APG-3288 has received investigational new drug (IND) clearance from the U.S. FDA, marking another major expansion to the company's global
- 11mo agoAAPGAscentage Pharma to Present at 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswireROCKVILLE, Md. and SUZHOU, China, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ:AAPG, HKEX: 6855)) ("Ascentage Pharma" or the "Company"), a global, commercial stage, integrated
- 11mo agoAAPGASH 2025 | Updated Data for Ascentage Pharma's Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line TreatmentGlobeNewswire76.7% complete cytogenetic response rate achieved in patients who failed second-generation TKI first-line therapy Molecular responses continue to deepen with extended treatment duration, reaching 60% major molecular
- 11mo agoAAPGASH 2025 | Ascentage Pharma Presents First Dataset from Phase III POLARIS-1 Study of Olverembatinib in Newly Diagnosed Ph+ ALL Shows a Best MRD-Negativity CR Rate Exceeding 60%GlobeNewswireBy the end of 3 induction cycles, the best minimal residual disease (MRD) negativity rate and the MRD-negative complete response (CR) rate were 66.0% and 64.2%, respectivelyHigh-risk IKZF1plus patients showed 90%
- 11mo agoAAPGASH 2025 | Ascentage Pharma Presents Four-Year Follow-Up Data from Registrational Phase II Study of Olverembatinib, Reaffirming Differentiated Long-Term Efficacy and Safety in TKI-Resistant/Intolerant CML-CPGlobeNewswireDramatically improved disease control with 21.2 months vs. 2.9 months median event-free survival (EFS) Favorable safety profile with 7% vascular occlusion rate Broad patient benefit with proven effectiveness even in
- 11mo agoAAPGASH 2025 | Ascentage Pharma Presents Encouraging Data from Phase Ib/II Study of Bcl-2 Inhibitor Lisaftoclax in Venetoclax–Exposed Patients with Myeloid MalignancesGlobeNewswirePreliminary clinical evidence of Lisaftoclax overcoming venetoclax resistance in myeloid malignancies with a 31.8% overall response rate(ORR) in this subgroup of patients80% ORR achieved in newly diagnosed high-risk
- 11mo agoAAPGAscentage Pharma Presents Pivotal China Registrational Study Data for Lisaftoclax in Oral Report at 2025 American Society of Hematology (ASH) Annual MeetingGlobeNewswireLisaftoclax monotherapy demonstrated significant and durable clinical efficacy and a manageable safety profile in patients with heavily pretreated BTK-refractory R/R CLL/SLL, underscoring its utility as a potential new
- 11mo agoAAPGAscentage Pharma to Host Webcast Highlighting Key Data from ASH 2025GlobeNewswireROCKVILLE, Md. and SUZHOU, China, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ:AAPG, HKEX: 6855)) ("Ascentage Pharma" or the "Company"), a global, commercial stage, integrated
- 11mo agoAAPGAscentage Pharma Announces Publication of Olverembatinib Phase Ib Safety, Efficacy and Novel Mechanism Data in Gastrointestinal Stromal Tumors in Nature's Signal Transduction and Targeted TherapyGlobeNewswireLargest prospective clinical trial to-date in a rare subtype of GIST ROCKVILLE, Md. and SUZHOU, China, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International Inc. (NASDAQ:AAPG, HKEX: 6855)), a global,
- 12mo agoAAPGAscentage Pharma to Participate in Three Upcoming Investor Conferences in December 2025GlobeNewswireROCKVILLE, Md. and SUZHOU, China, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ:AAPG, HKEX: 6855)) ("Ascentage Pharma" or the "Company"), a global, commercial stage, integrated
- 1y agoAAPGAscentage Pharma to Present Data from Two Clinical Studies for Bcl-2 Inhibitor Lisaftoclax, Including an Oral Report, at ASH 2025GlobeNewswireROCKVILLE, Md. and SUZHOU, China, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International Inc. (NASDAQ:AAPG, HKEX: 6855)), a global, commercial stage, integrated biopharmaceutical company engaged in the
- 1y agoAAPGAscentage Pharma to Present Data from Multiple Studies of Olverembatinib, Including the First Dataset from POLARIS-1 Study, at ASH 2025GlobeNewswireROCKVILLE, Md. and SUZHOU, China, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International Inc. (NASDAQ:AAPG, HKEX: 6855)), a global, commercial stage, integrated biopharmaceutical company engaged in the
- 1y agoAAPGAscentage Pharma to Participate in Two Upcoming Investor Conferences in November 2025GlobeNewswireROCKVILLE, Md. and SUZHOU, China, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ:AAPG, HKEX: 6855)) ("Ascentage Pharma" or the "Company"), a global, commercial stage, integrated
- 1y agoAAPGAscentage Pharma to Participate in Three Upcoming Investor Conferences in October 2025GlobeNewswireROCKVILLE, Md. and SUZHOU, China, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ:AAPG, HKEX: 6855)) ("Ascentage Pharma" or the "Company"), a global, commercial stage, integrated
- 1y agoAAPGAscentage Pharma Group International (AAPG) Presents At Citi's Biopharma Back To School Conference TranscriptEarnings Call Transcripts
- 1y agoAAPGAscentage Pharma to Participate in Three Upcoming Investor Conferences in September 2025GlobeNewswireROCKVILLE, Md. and SUZHOU, China, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ:AAPG, HKEX: 6855)) ("Ascentage Pharma" or the "Company"), a global, commercial stage, integrated
- 1y agoAAPGAscentage Pharma Reports 2025 Interim Unaudited Six Months Financial Results and Business UpdatesGlobeNewswireProduct sales from Olverembatinib in the first half of 2025 increased 93% year-over-year to US$30.3 million (RMB217.4 million), primarily attributable to the expansion of NRDL coverageCommenced commercial sales of
- 1y agoAAPGAscentage Pharma Announces Global Registrational Phase III Study of Lisaftoclax for First-line Treatment of Patients with Higher-Risk Myelodysplastic Syndrome Cleared by US FDA and EMAGlobeNewswireROCKVILLE, Md. and SUZHOU, China, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ:AAPG, HKEX: 6855)), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development
- 1y agoAAPGAscentage Pharma to Report 2025 Six Month Interim Results and Provide Corporate Update on August 20, 2025GlobeNewswireROCKVILLE, Md. and SUZHOU, China, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ:AAPG, HKEX: 6855)) ("Ascentage Pharma" or the "Company"), a global biopharmaceutical company dedicated to
- 1y agoAAPGAscentage Pharma to Participate in Evercore China Biotech SummitGlobeNewswireROCKVILLE, Md. and SUZHOU, China, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ:AAPG, HKEX: 6855)) ("Ascentage Pharma" or the "Company"), a global biopharmaceutical company dedicated to
- 1y agoAAPGAscentage Pharma to Participate in BTIG Virtual Biotechnology Conference 2025GlobeNewswireROCKVILLE, Md. and SUZHOU, China, July 23, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ:AAPG, HKEX: 6855)) ("Ascentage Pharma" or the "Company"), a global biopharmaceutical company dedicated to
- 1y agoAAPGAscentage Pharma Announces Closing of Placement Shares in Top-Up PlacementGlobeNewswireROCKVILLE, Md. and SUZHOU, China, July 17, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ:AAPG, HKEX: 6855)) ("Ascentage Pharma" or the "Company"), a global biopharmaceutical company dedicated to
- 1y agoAAPGAscentage Pharma Announces Pricing of Top-Up PlacementGlobeNewswireROCKVILLE, Md. and SUZHOU, China, July 14, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International Inc. (NASDAQ:AAPG, HKEX: 6855)) ("Ascentage" or the "Company"), a global biopharmaceutical company dedicated to